Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Bataller · SciRah

Researcher profile · Semantic Scholar

A. Bataller

Share profile

A. Bataller — researcher profile on SciRah

h-index: 20
Works: 179
Citations: 1,309

Most-cited papers

Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia
Sara K. Silbert, Alexander W. Rankin, Chloe N. Hoang, A. Semchenkova +77 more
2025Blood51 citations Open access
Semantic Scholar
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients
C. Willekens, A. Bazinet, Samy Chraibi, A. Bataller +25 more
2025Blood Cancer Journal36 citations Open access
Semantic Scholar
Oral decitabine/cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukemia: a phase 2 study
A. Bazinet, G. Garcia-Manero, N. Short, Y. Alvarado +21 more
2024The Lancet Haematology25 citations Open access
Semantic Scholar
Reduced-dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: results of a single-centre phase 2 trial
A. Bazinet, H. Kantarjian, A. Bataller, N. Pemmaraju +16 more
2024The Lancet Haematology20 citations
Semantic Scholar
Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
N. Jain, A. Ferrajoli, M. Swaminathan, P. Reville +28 more
2024Blood17 citations
Semantic Scholar
Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements
A. Bataller, Hannah Goulart, G. Issa, C. Dinardo +17 more
2025Leukemia13 citations
Semantic Scholar
A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS‐like tyrosine kinase 3 (FLT3)‐mutated acute myeloid leukemia
A. Bazinet, A. Bataller, T. Kadia, Naval G. Daver +11 more
2025Cancer13 citations
Semantic Scholar
Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy
Wei-Ying Jen, Koiji Sasaki, F. Ravandi, T. Kadia +14 more
2024Blood Advances12 citations Open access
Semantic Scholar
Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score–matched study
A. Bataller, Koiji Sasaki, Samuel Urrutia, G. Montalban-Bravo +22 more
2025Blood Cancer Journal11 citations Open access
Semantic Scholar
DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study
C. Gurnari, Hideki Makishima, Arda Durmaz, E. Attardi +29 more
2025Leukemia9 citations
Semantic Scholar
Combination Strategies with Menin Inhibitors for Acute Leukemia.
G. Issa, Sheng F. Cai, A. Bataller, H. Kantarjian +1 more
2025Blood Cancer Discovery8 citations
Semantic Scholar
TP53 Y220C mutations in patients with myeloid malignancies
G. Gener-Ricos, J. Bewersdorf, S. Loghavi, A. Bataller +15 more
2024Leukemia and Lymphoma7 citations
Semantic Scholar
Consolidation with CAR T-cell therapy may abrogate the need for allogeneic stem cell transplant in patients with relapsed B-cell acute lymphoblastic leukemia after receiving dose-dense mini-hyper-CVD with inotuzumab ozogamicin and blinatumomab
Hannah Goulart, E. Jabbour, Nitin Jain, F. Ravandi +10 more
2025Blood6 citations
Semantic Scholar
Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm
A. Bataller, G. Gener-Ricos, Emmanuel Almanza-Huante, K. Chien +14 more
2024Blood Advances6 citations Open access
Semantic Scholar
Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes
A. Bazinet, A. Bataller, K. Chien, Koiji Sasaki +33 more
2026Blood Cancer Journal5 citations Open access
Semantic Scholar
A phase 2 trial of CPX-351 combined with venetoclax in relapsed or refractory acute myeloid leukemia
T. Kadia, Wei-Ying Jen, A. Bataller, A. Bazinet +17 more
2025American journal of hematology/oncology5 citations
Semantic Scholar
MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukemia
Wei-Ying Jen, Gui-Lin Tang, E. Kugler, J. Croden +21 more
2025British Journal of Haematology5 citations Open access
Semantic Scholar
The addition of inotuzumab ozogamicin to frontline hyper-CVAD and sequential blinatumomab leads to durable survival outcomes in adults with newly diagnosed B-cell acute lymphoblastic leukemia: Four-year follow-up of a phase 2 study
Hannah Goulart, H. Kantarjian, Nitin Jain, Rita Khouri +13 more
2025Blood4 citations
Semantic Scholar
Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapy
A. Bazinet, S. Loghavi, Yue-Huan Wei, A. Bataller +26 more
2025Leukemia4 citations
Semantic Scholar
Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia
Nitin Jain, A. Ferrajoli, M. Swaminathan, J. Burger +30 more
2025Blood4 citations
Semantic Scholar
Decitabine-cedazuridine in patients with MDS and TP53 mutations
Samuel Urrutia, K. Sasaki, A. Bataller, H. Kantarjian +10 more
2025Blood Advances4 citations Open access
Semantic Scholar
Outcomes and Patterns of Relapse of NPM1 mutated acute myeloid leukemia treated with venetoclax based therapies
Wei-Ying Jen, S. Loghavi, A. Bazinet, A. Bataller +16 more
2025American journal of hematology/oncology4 citations Open access
Semantic Scholar
Current Treatment Strategies for FLT3-Mutated Acute Myeloid Leukemia in Patients not Candidates for Intensive Chemotherapy
A. Bataller, N. Short, N. Daver, M. Yilmaz +2 more
2025Current Oncology Reports4 citations
Semantic Scholar
FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML.
Reeja Raj, Samanta Catueno, Amber Gibson, David McCall +19 more
2025Blood4 citations
Semantic Scholar
Clinical Outcomes of Adult Patients with Newly Diagnosed Mixed Phenotype Acute Leukemia
Hannah Goulart, F. Ravandi, N. Short, Nitin Jain +24 more
2025JCO Precision Oncology4 citations
Semantic Scholar
Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.
Thura Win Htut, Jeannot Kekedjian, N. Short, A. Bazinet +21 more
2026Haematologica3 citations Open access
Semantic Scholar
Immunophenotypic changes following menin inhibition in acute myeloid leukemia
S. Loghavi, Aziz Farhat, Trevor Jamison, Georgina El Hajjar +21 more
2026Leukemia3 citations Open access
Semantic Scholar
Phase I/II study of decitabine/cedazuridine (ASXT727), venetoclax, and gilteritinib for patients with FLT3-mutated Acute Myeloid Leukemia or high-risk myelodysplastic syndrome
Roberta S. Azevedo, N. Short, A. Bataller, N. Daver +16 more
2025Blood3 citations
Semantic Scholar
Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia
G. Montalban-Bravo, S. Loghavi, Ziyi Li, K. Chien +28 more
2025Blood Advances3 citations
Semantic Scholar
Oral decitabine/cedazuridine in combination with venetoclax in treatment-naïve high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia: Updates of a Phase 1/2 clinical trial
A. Bataller, I. Bouligny, A. Bazinet, G. Montalban-Bravo +16 more
2025Blood3 citations
Semantic Scholar
Cladribine With Low‐Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia
T. Kadia, A. Bataller, A. Bazinet, G. Borthakur +26 more
2026American journal of hematology/oncology2 citations
Semantic Scholar
Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).
G. Issa, Branko Cuglievan, Georgina El Hajjar, Wei-Ying Jen +28 more
2026Journal of Clinical Oncology2 citations Open access
Semantic Scholar
Incorporation of genomic determinants improves diagnostic accuracy of oligomonocytic chronic myelomonocytic leukemia.
G. Montalban-Bravo, Chong Wu, J. J. Rodríguez-Sevilla, Yue Wei +37 more
2026Blood Cancer Discovery2 citations
Semantic Scholar
A Phase 2 study of CPX‐351 in combination with venetoclax in patients with newly diagnosed high‐risk acute myeloid leukemia
Wei-Ying Jen, J. Croden, Emmanuel Almanza-Huante, C. Dinardo +15 more
2025HemaSphere2 citations Open access
Semantic Scholar
Mutation Dynamics from Diagnosis to Relapse in Acute Myeloid Leukemia with Chromosomal 7 Deletions
E. Kugler, Enes Dasdemir, A. Bataller, Bo-Fei Wang +15 more
2025Leukemia and Lymphoma2 citations
Semantic Scholar
Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemia
T. Kadia, Akhil Jain, C. Rausch, A. Bataller +12 more
2025Blood neoplasia2 citations
Semantic Scholar
Multimodal assessment of chronic myelomonocytic leukemia with extramedullary involvement reveals RAS pathway activation, adverse outcomes and epithelial-mesenchymal transition
S. Loghavi, Chen-Xuan Zang, Ziyi Li, D. Hammond +25 more
2025Blood2 citations
Semantic Scholar
Phase Ib/II Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia
Emmanuel Almanza, Wei-Ying Jen, C. Dinardo, K. Chien +13 more
2024Blood2 citations
Semantic Scholar
Advances in the management of higher-risk myelodysplastic syndromes: future prospects
G. Gener-Ricos, J. J. Rodríguez-Sevilla, Samuel Urrutia, A. Bataller +2 more
2024Leukemia and Lymphoma2 citations
Semantic Scholar
Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia
Aziz Farhat, Georgina El Hajjar, H. Kantarjian, Koiji Sasaki +18 more
2026Cancer1 citations Open access
Semantic Scholar
Performance of molecular scoring systems in hypomethylating agent-treated myelodysplastic neoplasms.
K. Chien, Ziyi Li, L. Lanino, N. Al Ali +31 more
2026Leukemia1 citations
Semantic Scholar
Ibrutinib with venetoclax in patients with relapsed/refractory chronic lymphocytic leukemia: A phase II study.
M. Swaminathan, A. Ferrajoli, Philip A. Thompson, J. Burger +28 more
2026Blood Cancer Discovery1 citations
Semantic Scholar
Asciminib for newly diagnosed chronic myeloid leukemia: Results from A phase II trial
F. Haddad, E. Jabbour, G. Issa, K. Sasaki +9 more
2025Blood1 citations
Semantic Scholar
Allogeneic stem cell transplantation-related outcomes in myelodysplastic syndromes.
A. Bazinet, G. Garcia-Manero, A. Bataller, Samuel Urrutia +16 more
2025Journal of Clinical Oncology1 citations
Semantic Scholar
A randomized, multicenter trial of shorter durations of hypomethylating agents in lower-risk Myelodysplastic Syndromes
I. Bouligny, H. Carraway, M. Sekeres, A. Dezern +24 more
2025Blood1 citations
Semantic Scholar
Impact of discordant revised versus molecular international prognostic scoring system risk in myelodysplastic syndrome
A. Bazinet, G. Montalban-Bravo, A. Bataller, D. Hammond +14 more
2025Leukemia1 citations
Semantic Scholar
A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes
I. Bouligny, K. Chien, G. Montalban-Bravo, A. Bazinet +22 more
2025Blood1 citations
Semantic Scholar
Complex cytogenetics in myeloid malignancies: A deconstruction analysis redefining complex karyotypes
A. Bataller, A. Bazinet, G. Montalban-Bravo, K. Chien +14 more
2025Blood1 citations
Semantic Scholar
Characteristics and survival outcomes of patients with myelodysplastic syndromes with isolated 11q deletion.
Kensuke Takaoka, R. Komrokji, K. Chien, G. Montalban-Bravo +15 more
2025Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis1 citations
Semantic Scholar
Evaluating the impact of stem cell transplantation in myelodysplastic syndrome using machine learning and comparative modeling
Ziyi Li, K. Chien, Yue Lyu, K. Sasaki +9 more
2025Blood1 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

T. Kadia×42
Invite
T. Kadia — researcher profile on SciRah
F. Ravandi×36
Invite
F. Ravandi — researcher profile on SciRah
N. Short×35
Invite
N. Short — researcher profile on SciRah
G. Montalban-Bravo×32
Invite
G. Montalban-Bravo — researcher profile on SciRah

×31

Invite

A. Bazinet — researcher profile on SciRah

Invite

C. Dinardo — researcher profile on SciRah

Invite

G. Issa — researcher profile on SciRah

H. Kantarjian×25

Invite

H. Kantarjian — researcher profile on SciRah

Invite

K. Chien — researcher profile on SciRah

Naval G. Daver×21

Invite

Naval G. Daver — researcher profile on SciRah

N. Pemmaraju×20

Invite

N. Pemmaraju — researcher profile on SciRah

Koiji Sasaki×19

Invite

Koiji Sasaki — researcher profile on SciRah